medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-19-62-66medsovet-2748Research ArticleХимиотерапия злокачественных опухолейMalignant tumor chemotherapyИксабепилон: новые перспективы использования при раке молочной железыIxabepilone: new perspectives for its use in breast cancerМещеряковА. А.MescheryakovA. A.

д.м.н., заведующий отделением химиотерапии и комбинированного лечения злокачественных опухолей

ЛубенниковаЕ. В.LubennikovaE. V.

к.м.н., врач-онколог отделения химиотерапии и комбинированного лечения злокачественных опухолей

АбрамовМ. Е.AbramovM. E.

к.м.н., ведущий научный сотрудник отделения химиотерапии и комбинированного лечения злокачественных опухолей

ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России, МоскваРоссияBlokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, MoscowRussian Federation2018111120180196266Copyright © Мещеряков А.А., Лубенникова Е.В., Абрамов М.Е., 20182018Мещеряков А.А., Лубенникова Е.В., Абрамов М.Е.Mescheryakov A.A., Lubennikova E.V., Abramov M.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2748

Несмотря на достижения последних лет, в основе лекарственного лечения рака молочной железы (РМЖ) по-прежнему лежит химиотерапия. Внедрение новых эффективных цитостатических агентов с благоприятным профилем токсичности остается актуальной задачей современной фармакологии в онкологии. Иксабепилон – представитель нового класса противоопухолевых препаратов, эпотилонов, продемонстрировал высокую эффективность в лечении РМЖ как при ранних стадиях, так и у больных, получивших 2 и более линии химиотерапии. В статье рассмотрены результаты основных исследований, а также последнего метаанализа исследований Иксабепилона при местнораспространенном и метастатическом РМЖ. Приведены результаты двух крупных рандомизированных исследований по изучению Иксабепилона в адъювантных режимах при раннем РМЖ с неблагоприятным прогнозом.

Despite significant advances in recent years, the drug therapy for breast cancer (BC) is still based on chemotherapy. The introduction of new effective cytostatic agents with a favorable toxicity profile is likely to remain an urgent objective for modern pharmacology in oncology. Ixabepilone, first in a new class of antineoplastic agents, the epothilones, has demonstrated high efficacy in the treatment of breast cancer both in its early stages and in patients, who have received 2 or more lines of chemotherapy. The article discusses the results of major studies, as well as the last meta-analysis of Ixabepilone studies in locally advanced and metastatic breast cancer. It presents the results of two large randomized studies of Ixabepilone in adjuvant regimens in patients with early breast cancer with an unfavourable prognosis.

иксабепилонтрижды негативный рак молочной железыхимиотерапияэпотилоныβIII-тубулинIxabepilonetriply negative breast cancerchemotherapyepothilonesβIII-tubulinReferencesParker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol., 2009, 27: 1160-1167.Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol., 2009, 27: 1160-1167.Rugo HS et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). Journal of Clinical Oncology, 2015, 33(21): 2361.Rugo HS et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). Journal of Clinical Oncology, 2015, 33(21): 2361.Cooper GM, Ganem D. The Cell: A Molecular Approach. Nature Medicine, 1997, 3(9): 1042-1042.Cooper GM, Ganem D. The Cell: A Molecular Approach. Nature Medicine, 1997, 3(9): 1042-1042.English DP, Roque DM, Santin АD. Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents? Expert Review OF Anticancer Therapy, 2013, 13(1): 63-74.English DP, Roque DM, Santin АD. Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents? Expert Review OF Anticancer Therapy, 2013, 13(1): 63-74.Sève P, Dumontet С. Is class III β-tubulin a predictive factor in patients receiving tubulinbinding agents The Lancet Oncology, 2008, 9(2): 168-175.Sève P, Dumontet С. Is class III β-tubulin a predictive factor in patients receiving tubulinbinding agents The Lancet Oncology, 2008, 9(2): 168-175.Dumontet C, Jordan MA, Lee FFY. Ixabepilone: targeting βIII-tubulin expression in taxaneresistant malignancies. Molecular Cancer Therapeutics, 2009, 8(1): 17-25.Dumontet C, Jordan MA, Lee FFY. Ixabepilone: targeting βIII-tubulin expression in taxaneresistant malignancies. Molecular Cancer Therapeutics, 2009, 8(1): 17-25.Lee FYF et al. Experimental Therapeutics, Preclinical Pharmacology-BMS-247550: A Novel Epothilone Analog with a Mode of Action Similar to Paclitaxel but Possessing Superior Antitumor Efficacy. Clinical Cancer Research, 2001, 7(5): 1429-1437.Lee FYF et al. Experimental Therapeutics, Preclinical Pharmacology-BMS-247550: A Novel Epothilone Analog with a Mode of Action Similar to Paclitaxel but Possessing Superior Antitumor Efficacy. Clinical Cancer Research, 2001, 7(5): 1429-1437.Low JA et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. Journal of Clinical Oncology, 2005, 23(12): 2726-2734.Low JA et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. Journal of Clinical Oncology, 2005, 23(12): 2726-2734.Thomas E. et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. Journal of Clinical Oncology, 2007, 25(23); 3399-3406.Thomas E. et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. Journal of Clinical Oncology, 2007, 25(23); 3399-3406.Perez EA et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. Journal of Clinical Oncology, 2007, 25(23): 3407-3414.Perez EA et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. Journal of Clinical Oncology, 2007, 25(23): 3407-3414.Fountzilas G et al. Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. PloS one, 2013, 8(7): e69256.Fountzilas G et al. Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. PloS one, 2013, 8(7): e69256.Rugo HS et al. A randomized, phase II, threearm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Research and Treatment, 2013, 139(2): 411-419.Rugo HS et al. A randomized, phase II, threearm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Research and Treatment, 2013, 139(2): 411-419.Smith JW et al. Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients. Breast Cancer Research and Treatment, 2013, 142(2): 381-388.Smith JW et al. Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients. Breast Cancer Research and Treatment, 2013, 142(2): 381-388.Li J, Ren J, Sun W. Systematic review of ixabepilone for treating metastatic breast cancer. Breast Cancer, 2017, 24(2): 171-179.Li J, Ren J, Sun W. Systematic review of ixabepilone for treating metastatic breast cancer. Breast Cancer, 2017, 24(2): 171-179.Официальная инструкция препарата Икземпра в РФPatient Information Leaflet for Ixempra in the Russian Federation.Thomas ES et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. Journal of Clinical Oncology, 2007, 25(33): 5210-5217.Thomas ES et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. Journal of Clinical Oncology, 2007, 25(33): 5210-5217.Sparano JA et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology, 2010, 28(20): 3256-3263.Sparano JA et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology, 2010, 28(20): 3256-3263.Fornier М. Ixabepilon plus capecitabin for breast cancer patients with an Early metastatic relapse after adjuvant chemotherapy: two clinical trials. Clinical Breast Cancer, 2010: 352-358.Fornier М. Ixabepilon plus capecitabin for breast cancer patients with an Early metastatic relapse after adjuvant chemotherapy: two clinical trials. Clinical Breast Cancer, 2010: 352-358.Rugo HS et al. Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials. Clinical Breast Cancer, 2018.Rugo HS et al. Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials. Clinical Breast Cancer, 2018.Valero V., Vrdoljak E., Xu B., et al. Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. Clin Breast Cancer, 2012 Aug, 12(4): 240-6.Valero V., Vrdoljak E., Xu B., et al. Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. Clin Breast Cancer, 2012 Aug, 12(4): 240-6.Osborne C. et al. Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer. Clinical breast cancer, 2018, 18(1): e89-e95.Osborne C. et al. Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer. Clinical breast cancer, 2018, 18(1): e89-e95.Vahdat LT et al. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Research and Treatment, 2013, 140(2): 341-351.Vahdat LT et al. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Research and Treatment, 2013, 140(2): 341-351.Baselga J et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. Journal of Clinical Oncology, 2008, 27(4): 526-534.Baselga J et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. Journal of Clinical Oncology, 2008, 27(4): 526-534.Saura C et al. Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker. The Oncologist, 2013, 18(7): 787-794.Saura C et al. Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker. The Oncologist, 2013, 18(7): 787-794.Yardley DA et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer. Breast Cancer Research and Treatment, 2017, 164(3): 649-658.Yardley DA et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer. Breast Cancer Research and Treatment, 2017, 164(3): 649-658.Campone M et al. UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer. European Journal of Cancer, 2018, 103: 184-194.Campone M et al. UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer. European Journal of Cancer, 2018, 103: 184-194.

The authors declare that there are no conflicts of interest present.